This trial is testing a combination of drugs to see if it's safe and effective in treating patients with metastatic breast cancer, specifically those with the BRCA mutation.
2 Primary · 3 Secondary · Reporting Duration: 5 years
Experimental Treatment
64 Total Participants · 1 Treatment Group
Primary Treatment: ABT-888 · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: